Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes good week.
It's gonna be one hell of a ride. I really do not expect many small PRs from here out. I do expect PRs for trial initiation of Myocell SDF-1 including partnership funding. Also a PR for our phase 3 Marvel restart. A PR for the arthritis phase 1 for Adipocell. 10Q with more revenues. Possibly PRs pertaining to updates on out over seas trials such as the one in India. Imo
Definitely and we've been green for 2 days... And now above .01
As soon as we get our phase 3 restarted... This thing is gonna blow up. I guarantee it.
Lol quote "the volume was anemic.... Blah blah blah "
Lol lol lol lmao!!
I agree with you 100%
It was 700K before the last 5min I watched it happen
Interesting buying toward right now at market close
Sunrise, FL – March 17, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB), an emerging enterprise in the regenerative medicine / cellular therapy industry is pleased to announce, following the release of its Form 10-K Annual Report, key 2014 accomplishments including but not limited to:
1. 2. 3. 4. 5.
A 2,040% increase in year over year revenues to $2.1 million in 2014 from $0.1 million in 2013,
A 28% decrease in year over year net loss to ($2.25) million in 2014 from ($3.14) million in 2013,
A 42% decrease in year over year cash used in operating activities to $1.1 million in 2014 from $1.9 million in 2013,
A 20% reduction ($2.3 million) in year over year current liabilities to $11.1 million at December 31, 2014 from $13.4 million at December 31, 2013, and
A 20% reduction in the Company’s working capital deficit.
“Bioheart is moving in the right direction,” said Mike Tomas, President and Chief Executive Officer. “We are extremely proud of what we have accomplished in 2014 and through an extraordinary effort have set the stage for continuing improvements in both income statement and balance sheet performance in 2015. In 2015, we will continue our efforts to reshape Bioheart into a growth oriented, profit generating company capable of delivering regenerative / cellular therapies and products globally while advancing our clinical development pipeline to market. In the coming months, we look forward to announcing new strategic relationships that will introduce new opportunities for growth as well as jump starting long delayed clinical programs. I extend my sincere thanks to Dr. William P. Murphy, Jr., our Chairman, our Board of Director, Kristin Comella, our Chief Scientific Officer, the Bioheart Team and most especially you, our shareholders for your continuing support, commitment and dedication to our Company. We are excited about Bioheart’s future and we look forward to keeping you posted on our progress.”
http://www.bioheartinc.com/assets/press/2BioheartTouts2014Accomplishments;SeeksMorein2015.pdf
Yes exactly. I'm glad actual shareholders understand me.
It serves as proof that our next big project with a potential partnership, Myocell SDF-1, is on the exact track to success since other scientific articles are able to confirm what we already know imo
llustrative is Bioheart, a Sunrise-based biosciences firm that offers huge promise with its MyoCell therapy, composed of muscle cells that are injected into the scar tissue that has formed in the hearts of patients suffering from heart failure. Clinical trials worldwide have been shown to lead to improved cardiac function and an improved quality of life. With a steady stream of positive clinical outcomes worldwide, Bioheart launched a new facility in South Africa, a stem cell institute, last fall.
http://www.sun-sentinel.com/opinion/commentary/sfl-florida-sees-big-benefits-from-stem-cell-research-20150320-story.html
Yes true. Mike stated this during the shareholder meeting. The company is also stressing that advancement of trials will be made possible only through revenues.
Check this out.
Ocata plans 100-patient study of eye treatment
http://www.telegram.com/article/20150317/NEWS/303179601/1237&template=MOBILE
Amazing future ahead for us shareholders.
I don't get what you're trying to say... But EVERYTHING LOOKS GOOD TO ME. REVENUES UP, DEBT DOWN, BUSINESS GROWING.
True.
Awesome growth!! 2015 is going to be HUGE for BioHeart IMO!!!
Excellent
Yes this company is on the track to success! Great volume today too. Break out soon, we need a PR update on phase 3. Revenues Are seeing the snow ball effect. IMO
10K out!
The secret. I'm ready. Let the third week of this month commence!!!
Woooohoooo!! Can't wait either, it's happening.
Jesus Christ!! It sounds like we're about to go hammer time in Japan!! It's happening...
Third week is the charm IMO
Yes the 10Q should be very telling for the revenues expected in 2015.
We just turned on the-yacht!! We haven't even set sail!!
Should we expect the 10K tomorrow morning?
It's happening.
Good volume maintains and price is stable. I see the light!
It's happening...
Their *
They exceeded that per they're trend!! Imo
I have been, definitely.
I can feel and hear the volcano begin to rumble...
http://en.m.wikipedia.org/wiki/Ocata_Therapeutics
We're we just added to the wiki?
Party time!!!